Based on the Organon & Co stock forecast from 2 analysts, the average analyst target price for Organon & Co is USD 19.00 over the next 12 months. Organon & Co’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Organon & Co is Slightly Bearish, which is based on 5 positive signals and 9 negative signals. At the last closing, Organon & Co’s stock price was USD 15.03. Organon & Co’s stock price has changed by -6.30% over the past week, -16.69% over the past month and +37.26% over the last year.
No recent analyst target price found for Organon & Co
No recent average analyst rating found for Organon & Co
Company Overview Organon & Co
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey. Read Less
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a l...Read More
Frequently Asked Questions About Organon & Co (OGN) Stock
Based on ratings from 2 analysts Organon & Co's stock is Under-perform. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, 1 sell and 1 hold ratings.
OGN stock's dividend yield is 6.25%.
Our analysis grades OGN stock's dividend yield at A+. This means that OGN stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this OGN may be a good dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for OGN is USD 19.00 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 18.
OGN stock's Price/Earning ratio is 4.84.
Our analysis grades OGN stock's Price / Earning ratio at A+. This means that OGN stock's Price/Earning ratio is above 0% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this OGN may be undervalued for its sector.
The last closing price of OGN's stock was USD 15.03.
The most recent market capitalization for OGN is USD 4.84B.
Based on targets from 2 analysts, the average taret price for OGN is projected at USD 19.00 over the next 12 months.
This means that OGN's stock price may go up by +26.41% over the next 12 months.
We can't find any ETFs which contains Organon & Co's stock.
As per our most recent records Organon & Co has 10,000 Employees.
Organon & Co's registered address is 30 Hudson Street, Jersey City, NJ, United States, 07302.
You can get more information about it from Organon & Co's website at https://www.organon.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Organon & Co (OGN) Stock
Based on ratings from 2 analysts Organon & Co's stock is Under-perform. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, 1 sell and 1 hold ratings.
OGN stock's dividend yield is 6.25%.
Our analysis grades OGN stock's dividend yield at A+. This means that OGN stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this OGN may be a good dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for OGN is USD 19.00 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 18.
OGN stock's Price/Earning ratio is 4.84.
Our analysis grades OGN stock's Price / Earning ratio at A+. This means that OGN stock's Price/Earning ratio is above 0% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this OGN may be undervalued for its sector.
The last closing price of OGN's stock was USD 15.03.
The most recent market capitalization for OGN is USD 4.84B.
Based on targets from 2 analysts, the average taret price for OGN is projected at USD 19.00 over the next 12 months.
This means that OGN's stock price may go up by +26.41% over the next 12 months.
We can't find any ETFs which contains Organon & Co's stock.
As per our most recent records Organon & Co has 10,000 Employees.
Organon & Co's registered address is 30 Hudson Street, Jersey City, NJ, United States, 07302.
You can get more information about it from Organon & Co's website at https://www.organon.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for OGN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
